Soluble CD8 and ICAM-1 in serum and CSF of MS patients treated with 6-methylprednisolone

D. Franciotta, G. Piccolo, E. Zardini, R. Bergamaschi, V. Cosi

Research output: Contribution to journalArticle

Abstract

Objective - We studied the effects of large doses of 6-methylprednisolone (6-MP) on serum and cerebrospinal fluid (CSF) soluble CD8 (sCD8) and intercellular adhesion molecule-1 (sICAM-1) levels in clinically active multiple sclerosis (MS) patients. Material and methods - Paired serum and CSF samples were from 16 patients with definite MS, treated with 6-MP (1 g daily for 6 d) during an active phase of the disease. sCD8 and sICAM-1 levels were determined with ELISA before and after the therapy. Results - Before 6-MP treatment, sCD8 levels in CSF were higher in MS patients than in patients with noninflammatory neurological disease and in healthy controls; sICAM-1 levels in serum and in CSF were higher in MS patients than in the two control groups. Ten of the 16 patients showed clinical improvement at the end of the treatment. After the therapy, serum and CSF sCD8 levels increased, whereas serum and CSF sICAM-1 levels decreased. There was no correlation between clinical improvement and laboratory parameters. We evaluated sCD8 and sICAM-1 in serum samples from 10 patients 6 months after the 6-MP treatment, when the disease was clinically silent. Neither sCD8 nor sICAM-1 levels differed from those of the control groups. Conclusions - Our results suggest that high doses of 6-MP can influence serum and CSF sCD8 and sICAM-1 levels inactive MS. At least part of the efficacy of corticosteroid treatment in MS might be ascribed to its effect both on the suppressive circuits of immune response, and on the expression of an adhesion molecule that favours lymphocyte trafficking across the blood-brain barrier.

Original languageEnglish
Pages (from-to)275-279
Number of pages5
JournalActa Neurologica Scandinavica
Volume95
Issue number5
Publication statusPublished - 1997

Fingerprint

Methylprednisolone
Intercellular Adhesion Molecule-1
Multiple Sclerosis
Cerebrospinal Fluid
Serum
Therapeutics
Control Groups
Blood-Brain Barrier
Adrenal Cortex Hormones
Enzyme-Linked Immunosorbent Assay
Lymphocytes

Keywords

  • Cerebrospinal fluid
  • Methylprednisolone
  • Multiple sclerosis
  • Soluble CD8
  • Soluble ICAM-1

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Soluble CD8 and ICAM-1 in serum and CSF of MS patients treated with 6-methylprednisolone. / Franciotta, D.; Piccolo, G.; Zardini, E.; Bergamaschi, R.; Cosi, V.

In: Acta Neurologica Scandinavica, Vol. 95, No. 5, 1997, p. 275-279.

Research output: Contribution to journalArticle

@article{5ee3cec34abb440dbe924e7ceba15d4f,
title = "Soluble CD8 and ICAM-1 in serum and CSF of MS patients treated with 6-methylprednisolone",
abstract = "Objective - We studied the effects of large doses of 6-methylprednisolone (6-MP) on serum and cerebrospinal fluid (CSF) soluble CD8 (sCD8) and intercellular adhesion molecule-1 (sICAM-1) levels in clinically active multiple sclerosis (MS) patients. Material and methods - Paired serum and CSF samples were from 16 patients with definite MS, treated with 6-MP (1 g daily for 6 d) during an active phase of the disease. sCD8 and sICAM-1 levels were determined with ELISA before and after the therapy. Results - Before 6-MP treatment, sCD8 levels in CSF were higher in MS patients than in patients with noninflammatory neurological disease and in healthy controls; sICAM-1 levels in serum and in CSF were higher in MS patients than in the two control groups. Ten of the 16 patients showed clinical improvement at the end of the treatment. After the therapy, serum and CSF sCD8 levels increased, whereas serum and CSF sICAM-1 levels decreased. There was no correlation between clinical improvement and laboratory parameters. We evaluated sCD8 and sICAM-1 in serum samples from 10 patients 6 months after the 6-MP treatment, when the disease was clinically silent. Neither sCD8 nor sICAM-1 levels differed from those of the control groups. Conclusions - Our results suggest that high doses of 6-MP can influence serum and CSF sCD8 and sICAM-1 levels inactive MS. At least part of the efficacy of corticosteroid treatment in MS might be ascribed to its effect both on the suppressive circuits of immune response, and on the expression of an adhesion molecule that favours lymphocyte trafficking across the blood-brain barrier.",
keywords = "Cerebrospinal fluid, Methylprednisolone, Multiple sclerosis, Soluble CD8, Soluble ICAM-1",
author = "D. Franciotta and G. Piccolo and E. Zardini and R. Bergamaschi and V. Cosi",
year = "1997",
language = "English",
volume = "95",
pages = "275--279",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley Blackwell",
number = "5",

}

TY - JOUR

T1 - Soluble CD8 and ICAM-1 in serum and CSF of MS patients treated with 6-methylprednisolone

AU - Franciotta, D.

AU - Piccolo, G.

AU - Zardini, E.

AU - Bergamaschi, R.

AU - Cosi, V.

PY - 1997

Y1 - 1997

N2 - Objective - We studied the effects of large doses of 6-methylprednisolone (6-MP) on serum and cerebrospinal fluid (CSF) soluble CD8 (sCD8) and intercellular adhesion molecule-1 (sICAM-1) levels in clinically active multiple sclerosis (MS) patients. Material and methods - Paired serum and CSF samples were from 16 patients with definite MS, treated with 6-MP (1 g daily for 6 d) during an active phase of the disease. sCD8 and sICAM-1 levels were determined with ELISA before and after the therapy. Results - Before 6-MP treatment, sCD8 levels in CSF were higher in MS patients than in patients with noninflammatory neurological disease and in healthy controls; sICAM-1 levels in serum and in CSF were higher in MS patients than in the two control groups. Ten of the 16 patients showed clinical improvement at the end of the treatment. After the therapy, serum and CSF sCD8 levels increased, whereas serum and CSF sICAM-1 levels decreased. There was no correlation between clinical improvement and laboratory parameters. We evaluated sCD8 and sICAM-1 in serum samples from 10 patients 6 months after the 6-MP treatment, when the disease was clinically silent. Neither sCD8 nor sICAM-1 levels differed from those of the control groups. Conclusions - Our results suggest that high doses of 6-MP can influence serum and CSF sCD8 and sICAM-1 levels inactive MS. At least part of the efficacy of corticosteroid treatment in MS might be ascribed to its effect both on the suppressive circuits of immune response, and on the expression of an adhesion molecule that favours lymphocyte trafficking across the blood-brain barrier.

AB - Objective - We studied the effects of large doses of 6-methylprednisolone (6-MP) on serum and cerebrospinal fluid (CSF) soluble CD8 (sCD8) and intercellular adhesion molecule-1 (sICAM-1) levels in clinically active multiple sclerosis (MS) patients. Material and methods - Paired serum and CSF samples were from 16 patients with definite MS, treated with 6-MP (1 g daily for 6 d) during an active phase of the disease. sCD8 and sICAM-1 levels were determined with ELISA before and after the therapy. Results - Before 6-MP treatment, sCD8 levels in CSF were higher in MS patients than in patients with noninflammatory neurological disease and in healthy controls; sICAM-1 levels in serum and in CSF were higher in MS patients than in the two control groups. Ten of the 16 patients showed clinical improvement at the end of the treatment. After the therapy, serum and CSF sCD8 levels increased, whereas serum and CSF sICAM-1 levels decreased. There was no correlation between clinical improvement and laboratory parameters. We evaluated sCD8 and sICAM-1 in serum samples from 10 patients 6 months after the 6-MP treatment, when the disease was clinically silent. Neither sCD8 nor sICAM-1 levels differed from those of the control groups. Conclusions - Our results suggest that high doses of 6-MP can influence serum and CSF sCD8 and sICAM-1 levels inactive MS. At least part of the efficacy of corticosteroid treatment in MS might be ascribed to its effect both on the suppressive circuits of immune response, and on the expression of an adhesion molecule that favours lymphocyte trafficking across the blood-brain barrier.

KW - Cerebrospinal fluid

KW - Methylprednisolone

KW - Multiple sclerosis

KW - Soluble CD8

KW - Soluble ICAM-1

UR - http://www.scopus.com/inward/record.url?scp=0031010247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031010247&partnerID=8YFLogxK

M3 - Article

C2 - 9188901

AN - SCOPUS:0031010247

VL - 95

SP - 275

EP - 279

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

IS - 5

ER -